IL22 and Alzheimer disease: Its mechanism targets JAK1-dependent cytokine signaling, thereby modulating key inflammatory mediators implicated in AD pathogenesis, such as IL-4, IL-13, IL-22, IL-31, and IFN-γ [41,42].